Score and reliability increased to 11.68 6 2.71, n 5 123 ; and KR20 5 0.54 ; . Under negative-marking conditions, mean pre-course score for C3 was 3.31 6 2.50, n 5 134 ; and increased to 9.77 6 3.09, n 5 122 ; post-course. For C3, reliabilities at pre post-course were improved and comparable KR20 5 0.55, KR20 5 0.54 ; . Effect sizes for knowledge gain for C2 and C3 were large d 5 1.6 and d 5 2.3 ; and higher under negative-marking conditions. Implications: Number-right scoring may underestimate knowledge gain. The use of negative-marking may improve measurement reliability and more accurately reflect knowledge gain by reducing guessing. Assessment of Student Attitudinal and Cognitive Gains Resulting from a Course on School Medication Management. Thomas J. Reutzel, Midwestern University Chicago; Rohin N. Kasudia, Midwestern University Chicago; Seema J. Shah, Midwestern University Chicago. Objective: To assess the effect of a graduate seminar-type pedagogical approach on pharmacy students' confidence, valuation, and knowledge regarding the subject area of an elective course. Methods: An elective course in medication management in primary and secondary schools was taught to first and second year pharmacy students in 2005 and 2006. Grading was based on reading assignments, class discussions, and a small group brochure topic useful to school nurses, teachers, parents, etc. Brochures were judged by the primary instructor and three other faculty members. On the first and last day of class, a survey instrument was given to students enrolled in the course. Students used a Likert-type scale to score ten dimensions of course material on their level of confidence with the dimension and how important the dimension is. Knowledge levels were assessed via a 20-item true false test. Results: About 70 students completed both pre and post tests. Paired t-test results showed that these students realized significant gains p , 5 ; in confidence for seven of ten dimensions. Students realized significant losses in valuation for all ten dimensions. A significant increase in scores on the cognitive test was found. Implications: These results show that a seminar-type approach to a professional pharmacy elective can result in significant gains in student knowledge and confidence. Losses in valuation are surprising but may be due to confidence gains i.e., confidence means less perceived importance ; . Hopefully, a course like this will result in future pharmacists being more involved in this important area of drug therapy. Changes in Critical Thinking and Self-Directed Learning over an Academic School Year. Robert M. Cisneros, Campbell University. Objectives: The primary purpose of this study was to determine if surrogate measures of pharmacy student critical thinking and selfdirected learning changed over the 2005-2006 academic year at the Campbell University School of Pharmacy CUSOP ; . Methods: Subjects were consenting pharmacy students at CUSOP. All four professional years were represented. Three instruments were administered at the beginning end of the study period: the California Critical Thinking Skills Test CCTST ; , the California Critical Thinking Disposition Inventory CCTDI ; , and the Self-Directed Learning Readiness Scale SDLRS ; . Demographic information was also obtained. Results: One hundred thirty-seven students completed the CCTST and CCTDI and 138 students completed the SDLRS portions of the study. No statistically significant changes were found to have occurred in total scores overall and for the four individual subject groups P1, P2, P3, P4 ; . Mean student scores were above averages reported from comparable college students young adults who previously completed the instruments. Mean scores also were comparable to scores reported in similar pharmacy education research. Analysis of scale scores revealed significant differences in four categories: Inference CCTST scale ; and Cognitive Maturity, Confidence, and Openmindedness CCTDI scales ; . Significant correlations were also found between the three instruments and several achievement measures. Implications: Continued use of the instruments in a longitudinal manner is anticipated to further assess the students and curriculum. Without larger sample sizes, significant changes in scores may be difficult to detect unless moderate to large effect sizes occur which may not be realistic to expect. Similar studies of pharmacists may provide useful comparative data. Correlation between Depression and College Student Activities. Conrad Dhing, St. John's University; Greg R. Stein, St. John's University; Mackey L. Martha, St. John's University; Somnath Pal, St. John's University. Objective: Evaluate the correlation between depression and college student activities. Method: A cross-sectional study of six universities in New York City and Long Island was conducted in the Fall semester 2006. Full-time undergraduate students from St. John's University, Stony Brook SUNY ; , Fordham University, Lehman College CUNY ; , John Jay College CUNY ; , and Hunter College CUNY ; were asked to complete a survey, which included the Beck Depression Inventory BDI ; , questions on student activities and demographic information. Results: A convenience sample of 381 students completed the survey. Majority of the respondents were college seniors 35.4% ; , female 59.7% ; and resided off-campus 60.8% ; with either a family member or room mate 82.4% ; . The mean age of the respondents was 23.0 years SD 5 5.7 years ; with an average of 2.8 years SD 5 1.1 years ; spent in college. Of the 379 respondents who completed the BDI section, 20.3% selfreported having experienced episodes of depression while 35.0% could be considered as depressed based on their BDI scores. There were no correlation between the respondents' BDI scores and activities like number of hours spent working, exercising, socializing, studying, missing classes, number of extra-curricular activities and alcohol consumption. Conclusion: A thorough understanding of the effects of depression on college students' performance and success is very important to college administrators as well as to the students and their families. Designing Effective Websites: Innovation in Project-based Collaborative Learning. Andreas Karatsolis, Albany College of Pharmacy; Jason Swarts, North Carolina State University. Students of Pharmacy undergo an especially rigorous curriculum for the six years of their Pharm.D. program at the Albany College of Pharmacy. The content requirements are significant and they match the abilities and skills requirements that they are expected to showcase by the end of their instructional time. In most cases, the almost lock-step professional curriculum is expected to address both content and abilities such as communication skills ; , whereas elective courses are only meant to either fulfill a liberal arts requirement or complement the professional requirements. However, following ACPE's recent emphasis on experiential and applied models of education, an innovative science elective on Web Design was developed and offered in the Spring of 2006 at ACP, which provided pharmacy students with essential skills for professional growth. The course offered 4th and 5th year ACP students the opportunity to engage in a pharmacy related real-life web design project e.g. Medicare Part D website or Global Health perspectives portal ; , while collaborating with students of technical communication from North Carolina State University. The combination of experiential education and interdisciplinary, collaborative practice produced very successful results for students of both schools, as well as the ``clients'' of the websites, who were able to benefit from the contributions of content experts ACP ; and tool.

Interests: Information Retrieval, Pattern Recognition, Data Mining. Date of Birth: 17th August 1981. Education: Currently pursuing: M.E. Internet Science & Engg. ; , Dept. of Computer Science & Automation, Indian Institute of Science, Bangalore. Expected date of Completing: July 2005. ; CGPI up to 3rd Sem. ; : 6.3 8.0 B.E. Computer Science & Engg. Lakshmi Narayan College of Technology, Bhopal, India 1999-2003 ; . Obtained Marks in Percentage ; : 73.5 and elmiron.

Eligard ® 4 0-mg six-month product our commercial licensees have filed marketing authorizations for eligard 4 0-mg six-month product in two countries outside of north america. With that transaction now complete, we believe that we will renew their efforts in marketing the eligard franchise and eloxatin. Homeownership Nearly 75% of Columbia County residents owned homes in 2000. This is a higher percentage than the state of Wisconsin or the nation as shown in the following chart US Census, 2000b.
Registry to consolidate and study retrospective data obtained by retina specialists who have already used Visudyne as part of bi- or triple therapy. Based on the results of the ISS' and available data, we are planning to initiate one or more company sponsored studies to investigate the use of Visudyne in combination with anti-VEGF agents and steroids. Furthermore, certain of the ongoing ISS' are also investigating the potential benefit of reduced fluence, or low light levels, on the efficacy and safety of Visudyne. Eligard 3.75-mg one-month Product QLT USA was developing Eligard in Japan through a licensee, Sosei, for the treatment of prostate cancer. Sosei previously submitted the application for marketing approval of the Eligard 3.75 mg one-month formulation in Japan. After interaction with the Japanese Regulatory Authorities, they decided to withdraw the Eligard 3.75 mg one-month dossier from the Generic Division. As a result Sosei has notified us that it intends to terminate the license agreement for Eligard in Japan. We are currently assessing our future development plans for Eligard in Japan. AczoneTM Aczone is under development for the treatment of Rosacea, a chronic skin disorder that most often affects the central face including also the nose, forehead, cheeks and chin. We initiated a Phase II study in November 2005 and 12-week follow-up results were obtained in the third quarter 2006. In the overall population, the results showed that Aczone was no better than vehicle in reducing the signs and symptoms of papulopustular rosacea. However, in patients with more severe signs and symptoms, the study analysis showed an advantage of Aczone over the vehicle control. A decision on whether to proceed with a Phase III program using Aczone in Rosacea for this group diagnosed with more severe rosacea is on hold until after we get a decision from the FDA to remove the label requirement for blood testing for all patients treated with Aczone. Octreotide Atrigel - three-month Product Acromegaly We have developed a formulation of octreotide in the Atrigel delivery system for the treatment of the symptoms of acromegaly. Acromegaly is a chronic disease of middle-aged persons characterized by elongation and enlargement of bones of the extremities and certain head bones, especially the frontal bone and jaws. In the first quarter of 2006, we filed an IND for this study but in May 2006 announced that we would delay the initiation of the Phase IIa Atrigel octreotide program in acromegaly patients. This decision was made in cooperation with the U.S. Food and Drug Administration FDA ; following adverse event findings that occurred in an ongoing primate toxicology study designed to support repeated injections in patients. The FDA has required that we submit, and that the FDA be satisfied with, the final data from the ongoing toxicology study prior to initiating the 16-patient Phase IIa clinical program in acromegaly. We expect to submit the complete results of the toxicology study in the second quarter of 2007. Carcinoid Syndrome We have developed a formulation of octreotide in the Atrigel delivery system for the treatment of carcinoid syndrome. Carcinoid syndrome refers to the group of symptoms that occur in patients secondary to carcinoid tumors. This syndrome is characterized by hot red flushing of the face, as well as severe and debilitating diarrhea. The carcinoid tumors occur primarily in the appendix, ileum, rectum, or bronchi. We intend to submit to the FDA a Phase II pharmacokinetics protocol in carcinoid syndrome patients in the second quarter of 2007 at the same time as we submit the toxicology study results related to both the acromegaly and carcinoid syndrome programs. Our current plan is to accelerate the development of Octreotide in Carcinoid syndrome ahead of any development program in acromegaly. GHRP-1-Atrigel one-month Product We have developed a formulation of Growth Hormone Releasing Peptide-1, or GHRP-1, in the Atrigel delivery system for the treatment of malnutrition in end-stage renal disease patients on hemodialysis. Malnutrition is common in maintenance dialysis patients and leads to poor dialysis outcome. We initiated a phase IIa clinical trial in 2006 with the first patient treated in late 2006. The results of this study are expected during 2007. 11 and emend.

Eligard cost

Aortic y-graft, empirical order, understanding your health 9th edition, absinthe glow and sebaceous gland function. Scabies guidelines, abilify side effects, clinical trials edinburgh and does endep cause weight loss or lisinopril glucose.

Eligard prescribing information

Eligard contract

Eligard treatment, eligard and lupron, eligard doses, free eligard and eligard zolodex. Eligard lawsuit, eligard cost, eligard prescribing information and eligard contract or eligard prescription.